Evidence map›Paper›PMID 33449875›Full record

ArticleThe Journal of biological chemistry

Kinetics of cytochrome P450 3A4 inhibition by heterocyclic drugs defines a general sequential multistep binding process.

F Peter Guengerich, Kevin D McCarty, Jesse G Chapman

Abstract read
In one paragraph

Article in The Journal of biological chemistry. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Secondary Binding Site of CYP17A1 in Enhanced Sampling Simulations.Journal of chemical information and modeling · 2024
    Article
  6. Differential Effects of Clotrimazole on X-Ray Crystal Structures of Human Cytochromes P450 3A5 and 3A4.Drug metabolism and disposition: the biological fate of chemicals · 2023
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

F Peter GuengerichDepartment of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee, USA. Electronic address: f.guengerich@vanderbilt.edu.
Kevin D McCartyDepartment of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Jesse G ChapmanDepartment of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.

Funding

Metabolism of Carcinogens and Drugs by Human P450sR01GM118122 · NIGMS · VANDERBILT UNIVERSITY · PI GUENGERICH, F PETER · 2016 to 2023
$3.3M
High resolution Thermo Scientific Q-Exactive Orbitrap mass spectrometer for metabolomicsS10OD023514 · OD · VANDERBILT UNIVERSITY · PI SCHEY, KEVIN L · 2017 to 2017
$524k
NIGMS NIH HHS R01 GM118122NIH HHS S10 OD023514
6 · The paper itself

Abstract

Cytochrome P450 (P450) 3A4 is the enzyme most involved in the metabolism of drugs and can also oxidize numerous steroids. This enzyme is also involved in one-half of pharmacokinetic drug-drug interactions, but details of the exact mechanisms of P450 3A4 inhibition are still unclear in many cases. Ketoconazole, clotrimazole, ritonavir, indinavir, and itraconazole are strong inhibitors; analysis of the kinetics of reversal of inhibition with the model substrate 7-benzoyl quinoline showed lag phases in several cases, consistent with multiple structures of P450 3A4 inhibitor complexes. Lags in the onset of inhibition were observed when inhibitors were added to P450 3A4 in 7-benzoyl quinoline O-debenzylation reactions, and similar patterns were observed for inhibition of testosterone 6β-hydroxylation by ritonavir and indinavir. Upon mixing with inhibitors, P450 3A4 showed rapid binding as judged by a spectral shift with at least partial high-spin iron character, followed by a slower conversion to a low-spin iron-nitrogen complex. The changes were best described by two intermediate complexes, one being a partial high-spin form and the second another intermediate, with half-lives of seconds. The kinetics could be modeled in a system involving initial loose binding of inhibitor, followed by a slow step leading to a tighter complex on a multisecond time scale. Although some more complex possibilities cannot be dismissed, these results describe a system in which conformationally distinct forms of P450 3A4 bind inhibitors rapidly and two distinct P450-inhibitor complexes exist en route to the final enzyme-inhibitor complex with full inhibitory activity.

Indexed as

AnimalsBiocatalysisCloning, MolecularClotrimazoleCytochrome P-450 CYP3ACytochrome P-450 CYP3A InhibitorsEnzyme AssaysEscherichia coliGene ExpressionGenetic VectorsHumansHydroxyquinolinesIndinavirItraconazoleKetoconazoleKineticsClotrimazoleCytochrome P-450 CYP3ACytochrome P-450 CYP3A InhibitorsHydroxyquinolinesIndinavirItraconazoleKetoconazoleRecombinant ProteinsRitonavirsteroid hormone 6-beta-hydroxylaseSteroid Hydroxylasescytochrome P450enzyme inhibitorenzyme kineticsenzyme mechanismpre–steady-state kineticsUV–visible spectroscopy

Identifiers

PMID33449875
PMCPMC7948456

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.